We are live on ! Find out more
HEPA

Hepion Pharmaceuticals
HEPA

Delisted

HEPA was delisted on the 12th of May, 2025.

Back to rankings

31 hedge funds and large institutions have $9.74M invested in Hepion Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 9 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,111% more call options, than puts

Call options by funds: $678K | Put options by funds: $56K

8% more capital invested

Capital invested by funds: $9M → $9.74M (+$740K)

21% less funds holding

Funds holding: 39 → 31 (-8)

33% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 9

70% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 10

Holders
31
Holders Change
-8
Holders Change %
-20.51%
% of All Funds
0.49%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
6
Reduced
9
Closed
10
Calls
$678K
Puts
$56K
Net Calls
+$622K
Net Calls Change
+$199K

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$85.1K
2
IC
Ikarian Capital
Texas
+$32K
3
State Street
State Street
Massachusetts
+$28.7K
4
Group One Trading
Group One Trading
Illinois
+$8.84K
5
PFS
Prospera Financial Services
Texas
+$8.84K

Top Sellers

Rank Fund Capital Flow
1
VF
Virtu Financial
New York
-$57K
2
AC
Aristides Capital
Kentucky
-$56K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$44.2K
4
Bank of America
Bank of America
North Carolina
-$34.3K
5
ECM
ExodusPoint Capital Management
New York
-$28K
Name Holding Trade Value Shares
Change 		Change in
Stake
BFEC
26
Benjamin F. Edwards & Company
Missouri
$6K – – –
GWM
27
Geneos Wealth Management
Colorado
$6K – – –
Citigroup
28
Citigroup
New York
$5K +$4.42K +4 New
FDCDDQ
29
Federation des caisses Desjardins du Quebec
Quebec, Canada
$4.51K – – –
UBS Group
30
UBS Group
Switzerland
$2K -$8.84K -8 -80%
TRCT
31
Tower Research Capital (TRC)
New York
$2K +$2.21K +2 New
IA
32
IFP Advisors
Florida
$1K – – –
Wells Fargo
33
Wells Fargo
California
$1K – – –
VF
34
Virtu Financial
New York
– -$57K -50 Closed
AC
35
Aristides Capital
Kentucky
– -$56K -49 Closed
Bank of America
36
Bank of America
North Carolina
– -$34.3K -31 Closed
ECM
37
ExodusPoint Capital Management
New York
– -$28K -24 Closed
GCP
38
GSA Capital Partners
United Kingdom
– -$23K -21 Closed
SM
39
Sabby Management
Florida
– -$23K -20 Closed
CSS
40
Cubist Systematic Strategies
Connecticut
– -$18K -16 Closed
MIFH
41
Migdal Insurance & Financial Holdings
Israel
– -$2K -2 Closed
Rockefeller Capital Management
42
Rockefeller Capital Management
New York
– -$1K -1 Closed
US Bancorp
43
US Bancorp
Minnesota
– -$1K -1 Closed
1
2

HEPA Hedge Fund Activity: Q1 2022 in Review

31 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Hepion Pharmaceuticals (HEPA) for Q1 2022, worth a combined $9.74M — up 8.2% from $9M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of HEPA and 3 opened new positions — a net loss of 7 holders — while 9 trimmed existing stakes and 6 added.

The largest buyer was Renaissance Technologies, adding an estimated $85.1K. The largest seller was Virtu Financial, exiting entirely with an estimated $57K sold.

  • 31 institutional investors held Hepion Pharmaceuticals (HEPA) as of Q1 2022, down from 39 in Q4 2021.
  • Funds reported $9.74M of Hepion Pharmaceuticals stock for Q1 2022, up 8.2% quarter-over-quarter.
  • 3 funds opened new Hepion Pharmaceuticals positions in Q1 2022 and 10 closed out, a net change of -7 holders.
  • The largest Hepion Pharmaceuticals buyer in Q1 2022 was Renaissance Technologies, an estimated $85.1K added.
  • The largest Hepion Pharmaceuticals seller in Q1 2022 was Virtu Financial, an estimated $57K sold.

Based on aggregated 13F filings for Q1 2022.